Nanotherapeutics, Inc., today announced that it has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents.
Non-profit NanoBioNexus (NBN) - already widely acclaimed for its educational forums and nanobiotechnology expertise in the United States, has moved into the international leadership circles for innovative technologies with its International Alliance Initiative.
Houston Technology Center and Gulf Coast RCIC honored the nine Gulf Coast region companies that received awards from the ETF to date. Total ETF funding thus far to Gulf Coast region companies is over $13 million.
The Piedmont Triad Partnership has awarded seven new Focus Grants in three categories under the WIRED Focus Grants program. The grants program is one of several strategies being employed by the PTP to enhance workforce development initiatives as part of a larger effort to improve the global competitiveness of the Piedmont Triad Region.
Pharmaceuticals, Inc., a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, today announced that eight abstracts on ferumoxtytol, its lead product candidate, have been accepted for presentation at the American Society of Nephrology meeting.
Genetic Immunity LLC, a clinical stage biopharmaceutical company and a leader in the development of DNA based nanoparticle immunotherapies, announced today the completion of a $2 million dollar bridge financing.
JPK Instruments, the market leader in BioSPM, has further expanded the premises of its Berlin headquarters to take account of the continuing growth in personnel and the increasing demand for JPK products.
NaturalNano, Inc., a developer of advanced nanomaterials and additive technologies, announced it has signed an exclusive licensing agreement with the U.S. Naval Research Laboratory spanning multiple industries and broad patents in controlled-release nanomaterials.
Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation, announced today that its lead anti-cancer compound, IT-101, will be featured in a public television documentary series produced by Thirteen/WNET New York and the California Institute of Technology (Caltech).